141 related articles for article (PubMed ID: 27939522)
21. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Lopus M; Naik PK
Pharmacol Rep; 2015 Feb; 67(1):56-62. PubMed ID: 25560576
[TBL] [Abstract][Full Text] [Related]
22. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma.
Aneja R; Vangapandu SN; Lopus M; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2006 Jun; 69(6):1801-9. PubMed ID: 16517755
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel and improved antimitotic agents derived from noscapine.
Anderson JT; Ting AE; Boozer S; Brunden KR; Crumrine C; Danzig J; Dent T; Faga L; Harrington JJ; Hodnick WF; Murphy SM; Pawlowski G; Perry R; Raber A; Rundlett SE; Stricker-Krongrad A; Wang J; Bennani YL
J Med Chem; 2005 Nov; 48(23):7096-8. PubMed ID: 16279766
[TBL] [Abstract][Full Text] [Related]
24. Synergistic interaction of N-3-Br-benzyl-noscapine and docetaxel abrogates oncogenic potential of breast cancer cells.
Dash SG; Kantevari S; Pandey SK; Naik PK
Chem Biol Drug Des; 2021 Sep; 98(3):466-479. PubMed ID: 34107169
[TBL] [Abstract][Full Text] [Related]
25. Rational design of the microtubule-targeting anti-breast cancer drug EM015.
Aneja R; Lopus M; Zhou J; Vangapandu SN; Ghaleb A; Yao J; Nettles JH; Zhou B; Gupta M; Panda D; Chandra R; Joshi HC
Cancer Res; 2006 Apr; 66(7):3782-91. PubMed ID: 16585205
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of N-substituted noscapine analogues.
DeBono AJ; Xie JH; Ventura S; Pouton CW; Capuano B; Scammells PJ
ChemMedChem; 2012 Dec; 7(12):2122-33. PubMed ID: 23055449
[TBL] [Abstract][Full Text] [Related]
27. Structural investigations into the binding mode of a novel noscapine analogue, 9-(4-vinylphenyl) noscapine, with tubulin by biochemical analyses and molecular dynamic simulations.
Mahaddalkar T; Naik PK; Choudhary S; Manchukonda N; Kantevari S; Lopus M
J Biomol Struct Dyn; 2017 Aug; 35(11):2475-2484. PubMed ID: 27576773
[No Abstract] [Full Text] [Related]
28. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation.
Zhou J; Gupta K; Aggarwal S; Aneja R; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2003 Apr; 63(4):799-807. PubMed ID: 12644580
[TBL] [Abstract][Full Text] [Related]
29. A Comprehension into Target Binding and Spatial Fingerprints of Noscapinoid Analogues as Inhibitors of Tubulin.
Mandavi S; Verma SK; Banjare L; Dubey A; Bhatt R; Thareja S; Jain AK
Med Chem; 2021; 17(6):611-622. PubMed ID: 31951171
[TBL] [Abstract][Full Text] [Related]
30. Tryptone-stabilized gold nanoparticles target tubulin and inhibit cell viability by inducing an unusual form of cell cycle arrest.
Mahaddalkar T; Mehta S; Cheriyamundath S; Muthurajan H; Lopus M
Exp Cell Res; 2017 Nov; 360(2):163-170. PubMed ID: 28887025
[TBL] [Abstract][Full Text] [Related]
31. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth.
Landen JW; Hau V; Wang M; Davis T; Ciliax B; Wainer BH; Van Meir EG; Glass JD; Joshi HC; Archer DR
Clin Cancer Res; 2004 Aug; 10(15):5187-201. PubMed ID: 15297423
[TBL] [Abstract][Full Text] [Related]
32. Discovery of S-phase arresting agents derived from noscapine.
Anderson JT; Ting AE; Boozer S; Brunden KR; Danzig J; Dent T; Harrington JJ; Murphy SM; Perry R; Raber A; Rundlett SE; Wang J; Wang N; Bennani YL
J Med Chem; 2005 Apr; 48(8):2756-8. PubMed ID: 15828811
[TBL] [Abstract][Full Text] [Related]
33. Induction of reactive oxygen species-mediated autophagy by a novel microtubule-modulating agent.
Karna P; Zughaier S; Pannu V; Simmons R; Narayan S; Aneja R
J Biol Chem; 2010 Jun; 285(24):18737-48. PubMed ID: 20404319
[TBL] [Abstract][Full Text] [Related]
34. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma.
Landen JW; Lang R; McMahon SJ; Rusan NM; Yvon AM; Adams AW; Sorcinelli MD; Campbell R; Bonaccorsi P; Ansel JC; Archer DR; Wadsworth P; Armstrong CA; Joshi HC
Cancer Res; 2002 Jul; 62(14):4109-14. PubMed ID: 12124349
[TBL] [Abstract][Full Text] [Related]
35. Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
DeBono A; Capuano B; Scammells PJ
J Med Chem; 2015 Aug; 58(15):5699-727. PubMed ID: 25811651
[TBL] [Abstract][Full Text] [Related]
36. Insight into the Tubulin-Targeted Anticancer Potential of Noscapine and its Structural Analogs.
Kumar S; Sagar B; Gaur A; Shukla S; Pandey E; Gulati S
Anticancer Agents Med Chem; 2023; 23(6):624-641. PubMed ID: 35927808
[TBL] [Abstract][Full Text] [Related]
37. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
38. Rational design, chemical synthesis and cellular evaluation of novel 1,3-diynyl derivatives of noscapine as potent tubulin binding anticancer agents.
Patel AK; Meher RK; Reddy PK; Pedapati RK; Pragyandipta P; Kantevari S; Naik MR; Naik PK
J Mol Graph Model; 2021 Jul; 106():107933. PubMed ID: 33991960
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of noscapine analogues as microtubule-interfering agents.
Dai HL; Zheng JB; Lin M; Zheng J; Zhou FS; Dong XC; Guo L; Liu JW; Wen R
Yao Xue Xue Bao; 2012 Oct; 47(10):1347-57. PubMed ID: 23289148
[TBL] [Abstract][Full Text] [Related]
40. In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin).
Naik PK; Lopus M; Aneja R; Vangapandu SN; Joshi HC
J Comput Aided Mol Des; 2012 Feb; 26(2):233-47. PubMed ID: 22170255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
